Janus Henderson Group
VERV

Janus Henderson Group’s Verve Therapeutics VERV Stock Holding History

Janus Henderson Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,031
Closed -$169K – 2475
2025
Q2 		$169K Hold
15,031
– – ﹤0.01% 2346
2025
Q1 		$78.4K Hold
15,031
– – ﹤0.01% 2472
2024
Q4 		$84.5K Hold
15,031
– – ﹤0.01% 2513
2024
Q3 		$72.7K Hold
15,031
– – ﹤0.01% 2525
2024
Q2 		$73.3K Sell
15,031
-256
-2% -$1.61K ﹤0.01% 2508
2024
Q1 		$203K Buy
15,287
+35
+0.2% +$464 ﹤0.01% 2414
2023
Q4 		$212K Sell
15,252
-27
-0.2% -$335 ﹤0.01% 2413
2023
Q3 		$202K Buy
15,279
+24
+0.2% +$386 ﹤0.01% 2379
2023
Q2 		$286K Sell
15,255
-31
-0.2% -$516 ﹤0.01% 2271
2023
Q1 		$220K Buy
+15,286
New +$299K ﹤0.01% 2445
2022
Q4 		– Sell
-7,268
Closed -$250K – 2507
2022
Q3 		$250K Buy
+7,268
New +$232K ﹤0.01% 2289
2022
Q2 		– Sell
-690,011
Closed -$15.7M – 2689
2022
Q1 		$15.7M Sell
690,011
-472,785
-41% -$13.5M 0.01% 796
2021
Q4 		$41.2M Buy
1,162,796
+1,913
+0.2% +$80.4K 0.02% 609
2021
Q3 		$52.5M Sell
1,160,883
-252,888
-18% -$14.9M 0.02% 536
2021
Q2 		$79.8M Buy
+1,413,771
New +$58.7M 0.03% 434

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Janus Henderson Group's VERV Position: Q3 2025 in Review

Janus Henderson Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 15,031 shares — an estimated $169K sold.

Janus Henderson Group first reported a position in VERV in Q2 2021 and held it in 15 quarters. The position peaked at $79.8M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Janus Henderson Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Janus Henderson Group sold 15,031 Verve Therapeutics shares in Q3 2025, an estimated $169K.
  • Janus Henderson Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 15 quarters.
  • Janus Henderson Group's Verve Therapeutics position peaked at $79.8M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Janus Henderson Group's 13F filing for Q3 2025, filed 14 Nov 2025.